We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Catalyst (CPRX) Posts In-Line Q4 Loss, Pipeline in Progress
Read MoreHide Full Article
Catalyst Pharmaceuticals, Inc. (CPRX - Free Report) reported a loss of 6 cents per share in the fourth quarter of 2017, on par with the Zacks Consensus Estimate. The reported loss was wider than the year-ago loss of 5 cents.
Being a development-stage company, Catalyst Pharma does not have any approved product in its portfolio yet. Hence, the company did not generate any revenues in the quarter.
So far this year, Catalyst Pharma’s shares have rallied 74.2% compared with the industry’s gain of 4.4%.
Quarter in Detail
Research and development (R&D) expenses were $3.4 million, up 20.7% from the year-ago quarter. The costs included expenses related to ongoing studies and trials for Firdapse, costs associated with the Firdapse Expanded Access Program and expenses pertaining to the CPP-115 and generic Sabril programs.
General and administrative expenses totaled $2.1 million, up 41% from the year-ago quarter.
Pipeline Update
Currently, Catalyst Pharma has two candidates under development — Firdapse and CPP-115.
The company made significant progress with respect to the second phase III study evaluating Firdapse for the treatment of Lambert-Eaton Myasthenic Syndrome. Catalyst Pharma also successfully completed the required abuse liability studies that confirmed that Firdapse does not exhibit abuse potential.
The company also expects to enroll patients in its phase III study for MuSK antibody positive myasthenia gravis in the first half of 2018 and the proof-of-concept study for spinal muscular atrophy Type 3 in the second quarter of 2018.
Meanwhile, the company is on track to resubmit its new drug application for Firdapse in the first quarter of 2018 and is actively engaged in pre-commercialization activities for a potential launch of the same.
The company expects to complete enrollment in the phase III CMS (CMS-001) study before 2018-end and report top-line results it in the first quarter of 2019.
Catalyst Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Regeneron’s earnings per share estimates have moved up from $18.65 to $18.68 and from $21.56 to $21.60 for 2018 and 2019, respectively, in the last 30 days. The company pulled off a positive earnings surprise in three of the last four quarters, the average beat being 9.15%.
Ligand’s earnings per share estimates rose from $3.78 to $4.20 and $4.75 to $5.32 for 2018 and 2019, respectively, over the last 30 days. The company delivered positive earnings surprises in three of the trailing four quarters, the average beat being 24.88%. The company’s shares have rallied 64.6% in a year’s time.
Enanta Pharma delivered a positive earnings surprise in three of the last four quarters, with an average beat of 373.1%. The company’s shares have gained 193.6% over a year.
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others. Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Image: Bigstock
Catalyst (CPRX) Posts In-Line Q4 Loss, Pipeline in Progress
Catalyst Pharmaceuticals, Inc. (CPRX - Free Report) reported a loss of 6 cents per share in the fourth quarter of 2017, on par with the Zacks Consensus Estimate. The reported loss was wider than the year-ago loss of 5 cents.
Being a development-stage company, Catalyst Pharma does not have any approved product in its portfolio yet. Hence, the company did not generate any revenues in the quarter.
So far this year, Catalyst Pharma’s shares have rallied 74.2% compared with the industry’s gain of 4.4%.
Quarter in Detail
Research and development (R&D) expenses were $3.4 million, up 20.7% from the year-ago quarter. The costs included expenses related to ongoing studies and trials for Firdapse, costs associated with the Firdapse Expanded Access Program and expenses pertaining to the CPP-115 and generic Sabril programs.
General and administrative expenses totaled $2.1 million, up 41% from the year-ago quarter.
Pipeline Update
Currently, Catalyst Pharma has two candidates under development — Firdapse and CPP-115.
The company made significant progress with respect to the second phase III study evaluating Firdapse for the treatment of Lambert-Eaton Myasthenic Syndrome. Catalyst Pharma also successfully completed the required abuse liability studies that confirmed that Firdapse does not exhibit abuse potential.
The company also expects to enroll patients in its phase III study for MuSK antibody positive myasthenia gravis in the first half of 2018 and the proof-of-concept study for spinal muscular atrophy Type 3 in the second quarter of 2018.
Meanwhile, the company is on track to resubmit its new drug application for Firdapse in the first quarter of 2018 and is actively engaged in pre-commercialization activities for a potential launch of the same.
The company expects to complete enrollment in the phase III CMS (CMS-001) study before 2018-end and report top-line results it in the first quarter of 2019.
Catalyst Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Catalyst Pharmaceuticals, Inc. Price, Consensus and EPS Surprise | Catalyst Pharmaceuticals, Inc. Quote
Zacks Rank & Key Picks
Catalyst Pharma has a Zacks Rank #3 (Hold). A few better-ranked stocks from the same space are Regeneron (REGN - Free Report) , Ligand Pharmaceuticals (LGND - Free Report) and Enanta Pharma (ENTA - Free Report) . While Regeneronsports a Zacks Rank #1 (Strong Buy), Ligand andEnanta Pharma carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Regeneron’s earnings per share estimates have moved up from $18.65 to $18.68 and from $21.56 to $21.60 for 2018 and 2019, respectively, in the last 30 days. The company pulled off a positive earnings surprise in three of the last four quarters, the average beat being 9.15%.
Ligand’s earnings per share estimates rose from $3.78 to $4.20 and $4.75 to $5.32 for 2018 and 2019, respectively, over the last 30 days. The company delivered positive earnings surprises in three of the trailing four quarters, the average beat being 24.88%. The company’s shares have rallied 64.6% in a year’s time.
Enanta Pharma delivered a positive earnings surprise in three of the last four quarters, with an average beat of 373.1%. The company’s shares have gained 193.6% over a year.
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others. Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Download the new report now>>